Vaccinex, Inc. (VCNX) OTC

0.75

+0.02(+2.74%)

Updated at June 30 08:00PM

Currency In USD

Vaccinex, Inc.

Address

1895 Mount Hope Avenue

Rochester, NY 14620

United States of America

Phone

585 271 2700

Sector

Healthcare

Industry

Biotechnology

Employees

23

First IPO Date

August 09, 2018

Key Executives

NameTitlePayYear Born
Dr. Maurice Zauderer Ph.D.Co-Founder, Chief Executive Officer, President & Director437,2861946
Dr. Elizabeth E. Evans Ph.D.Chief Operating Officer and Senior Vice President of Discovery & Translational Medicine309,4081972
Dr. Ernest S. Smith Ph.D.Senior Vice President of Research & Chief Scientific Officer339,8811972
Ms. Jill Sanchez CPAChief Financial Officer01972

Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.